Compare ATLO & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | RZLT |
|---|---|---|
| Founded | 1903 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.2M | 187.3M |
| IPO Year | N/A | N/A |
| Metric | ATLO | RZLT |
|---|---|---|
| Price | $24.20 | $3.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.14 |
| AVG Volume (30 Days) | 23.1K | ★ 5.6M |
| Earning Date | 01-23-2026 | 02-11-2026 |
| Dividend Yield | ★ 3.27% | N/A |
| EPS Growth | ★ 82.57 | N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $60,568,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.63 | ★ N/A |
| Revenue Growth | ★ 18.60 | N/A |
| 52 Week Low | $16.09 | $1.07 |
| 52 Week High | $24.96 | $11.46 |
| Indicator | ATLO | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 63.47 | 52.08 |
| Support Level | $23.16 | $2.69 |
| Resistance Level | $24.96 | $2.92 |
| Average True Range (ATR) | 0.60 | 0.28 |
| MACD | 0.08 | 0.35 |
| Stochastic Oscillator | 64.60 | 99.14 |
Ames National Corporation is a United States-based bank holding company. It provides short-term and medium-term commercial, multi-family, and agricultural real estate loans, residential real estate loans, agricultural and business operating loans and lines of credit, equipment loans, vehicle loans, personal loans and lines of credit, home improvement loans and origination of mortgage loans for sale into the secondary market. The Banks also offer a variety of checking, savings and time deposits, cash management services, merchant credit card processing, safe deposit boxes, wire transfers, direct deposit and automated/video teller machine access. The banking segment generates revenues through personal, business, agricultural and commercial lending, and Others.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.